Stay updated with breaking news from Tom Graney. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Negma Group has converted 230 convertible bonds in Oxurion resulting in a EUR 575,000 capital increase. This is part of Negma Group's EUR 30 million Capital Commitment1 that will allow Oxurion to focus
Investegate announcements from Oxurion NV, Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Leuven, BELGIUM, Boston, MA, US - 11 April 2022 - 7.00 AM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a
Oxurion has successfully raised EUR >10 million from leading US and European healthcare investors in a private equity placement and Negma Group has converted 240 convertible bonds in Oxurion resulting
Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announces today that Tom Graney, Chief Executive Officer, will present at the 21st Annual ...